Helus Pharma Q2 Loss Widens On Higher Costs; Phase 3 Depression Data Due In Q4 2026
Helus Pharma (HELP) reported a wider Q2 loss of $103.09M, or $1.41 per share, due to higher costs. Operating expenses rose to $104.52M, with share-based compensation at $64.96M. The company has $171.07M in cash. HLP003 Phase 3 results are due in Q4 2026. Shares fell 13.53% on Monday.
How this was made

The 30-second read
Why it matters
The update combines a materially wider quarterly loss with explicit cost drivers (notably share-based compensation) and milestone timing (Phase 3 topline expected in Q4 2026, Phase 2 monotherapy trial starting Q1 2027). This mix typically shifts traders toward cash-burn and dilution-risk modeling while waiting for the next clinical readout.
Market read
Traders get a fresh quarterly cost and loss datapoint plus concrete clinical timeline markers that affect near-term valuation and risk pricing.
What to watch
Cash balance is $171.07M as of Sept. 30, which could moderate dilution fears if burn stabilizes; also, enrollment completion in PARADIGM may reduce execution risk into Q4 2026.
Background
Helus is a clinical-stage serotonergic agonist developer focused on depression (HLP003) and anxiety (HLP004), with Phase 3 PARADIGM enrollment completed and additional pivotal trials ongoing.
Ticker impact
Helus reported a wider FY27 Q2 loss to $103.09M as share-based compensation and clinical spending rose, alongside Phase 3 timing updates.
Likely downside pressure as investors weigh cost acceleration and delayed clinical milestones against the cash runway.
The article discloses a large jump in operating expenses driven by share-based compensation and clinical spending, plus Phase 3 topline timing and upcoming trial starts that extend the development timeline.
Market effects
Reinforces the biotech tape narrative that clinical-stage companies with rising opex and SBC face valuation pressure until clearer Phase 3 catalysts arrive.
Limited, company-specific move for US small-cap biotech.
Low, no cross-market policy or sector-wide regulatory trigger described.
Counterpoint
The cost increase is framed as continued advancement of HLP003 Phase 3 trials, so the market may be over-penalizing near-term burn ahead of topline.
Key entities
- companyHelus Pharma Inc.
Reported wider Q2 FY27 loss, higher operating expenses, and provided pipeline and trial timing updates.
- programHLP003 (PARADIGM)
Phase 3 program with enrollment completed; topline expected in Q4 2026, with additional pivotal trials ongoing.
- programHLP004
Generalized anxiety disorder program planning Phase 2 monotherapy trial in Q1 2027.
- executiveMichael Halstead
Appointed CEO to lead through late-stage development and commercialization.




